Metabolic syndrome (MetS) is a serious health condition that puts people at high risk of development of cardiovascular diseases including but not limited to heart disease, hypertension, stroke, atherosclerosis, retinopathy, nephropathy, etc. The pathogenesis and clinical features of MetS-associated cardiovascular diseases (MetS-CVD) have been well-studied in the past decades, but effective approaches to prevent and treat these diseases are limited. The MetS-CVDs occur as a result of the dysregulated glucose and lipid metabolism, associated with diabetes mellitus and obesity, which ultimately lead to increased oxidative stress and the activation of inflammatory pathways that mediate cellular and extracellular injury, pathological cardiovascular remodelling, and dysfunction. However, therapeutic strategies that specifically target these signalling pathways to prevent and/or treat MetS-CVDs remain limited.
In this Research Topic, we would like to create a forum for current advances on preclinical and clinical studies targeting these well-studied signalling pathways for prevent and/or treatment of MetS-CVDs. We welcome preclinical studies focusing on testing the effects of potential therapeutic strategies against the development of MetS-CVDs and defining the molecular mechanisms involved in cardiovascular diseases. We also expect clinical studies evaluating the efficacy and mechanisms of hypoglycaemic and non-hypoglycaemic drugs against the development of MetS-CVDs.
Topics of interest include but are not limited to:
• Preclinical studies testing the efficacy of potential therapeutic strategies against the development of MetS-CVDs, including heart disease, hypertension, stroke, atherosclerosis, retinopathy, nephropathy, etc.
• Clinical studies testing the efficacy of potential therapeutic strategies against the development of MetS-CVDs, including heart disease, hypertension, stroke, atherosclerosis, retinopathy, nephropathy, etc.
• The molecular mechanisms of potential therapeutic strategies that target cardiovascular glucose and lipid metabolism, oxidative stress, inflammation, cell death, and/or tissue remodeling.
• Preclinical and clinical studies on repurposing of approved clinical drugs for treatment MetS and CVDs and dissecting the underlying molecular mechanisms.
Metabolic syndrome (MetS) is a serious health condition that puts people at high risk of development of cardiovascular diseases including but not limited to heart disease, hypertension, stroke, atherosclerosis, retinopathy, nephropathy, etc. The pathogenesis and clinical features of MetS-associated cardiovascular diseases (MetS-CVD) have been well-studied in the past decades, but effective approaches to prevent and treat these diseases are limited. The MetS-CVDs occur as a result of the dysregulated glucose and lipid metabolism, associated with diabetes mellitus and obesity, which ultimately lead to increased oxidative stress and the activation of inflammatory pathways that mediate cellular and extracellular injury, pathological cardiovascular remodelling, and dysfunction. However, therapeutic strategies that specifically target these signalling pathways to prevent and/or treat MetS-CVDs remain limited.
In this Research Topic, we would like to create a forum for current advances on preclinical and clinical studies targeting these well-studied signalling pathways for prevent and/or treatment of MetS-CVDs. We welcome preclinical studies focusing on testing the effects of potential therapeutic strategies against the development of MetS-CVDs and defining the molecular mechanisms involved in cardiovascular diseases. We also expect clinical studies evaluating the efficacy and mechanisms of hypoglycaemic and non-hypoglycaemic drugs against the development of MetS-CVDs.
Topics of interest include but are not limited to:
• Preclinical studies testing the efficacy of potential therapeutic strategies against the development of MetS-CVDs, including heart disease, hypertension, stroke, atherosclerosis, retinopathy, nephropathy, etc.
• Clinical studies testing the efficacy of potential therapeutic strategies against the development of MetS-CVDs, including heart disease, hypertension, stroke, atherosclerosis, retinopathy, nephropathy, etc.
• The molecular mechanisms of potential therapeutic strategies that target cardiovascular glucose and lipid metabolism, oxidative stress, inflammation, cell death, and/or tissue remodeling.
• Preclinical and clinical studies on repurposing of approved clinical drugs for treatment MetS and CVDs and dissecting the underlying molecular mechanisms.
